G
GE HealthCare Technologies Inc.
GEHC · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
The Scanner Company That Secretly Wants to Be a Drug Company
Most investors are underwriting GEHC as a hardware cycle play with AI upside, but the real compounding engine is Pharmaceutical Diagnostics — contrast agents and radiopharmaceuticals consumed on every scan, with Flarcato poised to reshape cardiac imaging economics in a way that looks nothing like a capital equipment business. The hardware installed base is the distribution network; the drug pipeline is the profit engine investors haven't repriced yet.
Flowly Score
Apr 16 Close
+2%$73.20
Fair Value
$75.00
48
Below Averageat $73.20
Business Strength6/10
The installed-base flywheel and switching costs are genuinely durable, but ROIC compressing toward ten percent while ROE climbs is the financial equivalent of borrowing confidence — leverage flatters the equity return while the underlying business earns less on each incremental dollar deployed. PDx is the underappreciated gem, but the core imaging moat is narrowing at the edges faster than the bull case admits.
Financial Resilience5/10
Generating real free cash flow every single year earns real respect, and the Piotroski score reflects a business with genuine earning power — but the Altman Z sitting below 2.0 is not a number to wave away, and CapEx nearly doubling while FCF margins compress means the machine is working harder to stay in place rather than sprint forward.
Growth & Trajectory6/10
Flarcato is the single most interesting variable in the entire investment case — a proprietary radiopharmaceutical in a market shifting from SPECT to PET is not a modest upgrade story, it's a category reshaping that could make PDx the highest-return segment in the portfolio within three years. The record backlog and new product refresh cycle are real tailwinds, but mid-single-digit organic growth against a contracting China is an honest ceiling without software monetization.
Valuation4/10at $75.63
The stock is priced just above the neutral DCF scenario, which means you need the optimistic case to simply break even from here — a thin margin of safety for a business with compressing ROIC, a balance sheet that limits flexibility, and a transformational AI thesis that remains unproven in the revenue line. The market has already paid for some of the optionality.
Risk5/10
The China retreat is not a tail risk — it is happening in real time, and management has already explicitly budgeted for 2026 decline, which means the consensus model has some cover but geopolitical escalation could turn a managed retreat into a rout. The governance residue from decades inside a financial engineering empire is the slower-burning risk: cultural transformation at fifty-three thousand people cannot be declared in an investor day presentation.
GEHC is a fundamentally sound business priced for perfection on a flawed thesis. The market sees a steady medical equipment company with modest AI optionality; what it's missing is that Pharmaceutical Diagnostics — structurally uncorrelated to hospital capex cycles, consumed in volume on every scan, with proprietary manufacturing processes and a regulatory moat — is growing faster and carries superior economics to everything else in the portfolio. If Flarcato executes on its cardiac imaging opportunity, the mix shift toward higher-margin recurring drug revenue could reaccelerate ROIC from its current depressed trajectory, invalidating the bear case before it fully materializes. The direction of travel for this business over five years is probably upward, but the path is messier than the multiple implies. The innovation cycle is real — a record backlog, product refresh driving service capture rates higher, and an AI partnership building software revenue on top of the installed base all point toward a company that is genuinely evolving its business model rather than just repricing the legacy one. The spinoff has forced management focus in a way that decades inside a conglomerate never permitted, and operational discipline through the Heartbeat system is showing up in service delivery metrics. The open question is whether software revenue reaches critical mass before rising capex intensity fully erodes free cash generation. The single most specific risk is China — not abstractly, but concretely: United Imaging is a national champion with state backing winning hospital tenders on price and matching on quality at a moment when geopolitical friction makes US-branded equipment a procurement liability rather than a preference. If that revenue base declines sharply rather than gradually, GEHC loses its fastest-growing geography at precisely the moment its balance sheet leaves the least room for error, and the bull case math falls apart before Flarcato can rescue it.